hunan hansen pharmaceutical (002412.SZ) released its performance for the first three quarters, with a net income of 0.131 billion yuan, a year-on-year increase of 19.15%.

Zhitong Finance · Oct 28 23:21

Hunan Hansen Pharmaceutical (002412.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue...

According to the Zhixun Finance APP, Hunan Hansen Pharmaceutical (002412.SZ) released the third quarter report of 2024. In the first three quarters, the company achieved revenue of 0.694 billion yuan, a year-on-year increase of 1.44%. The net income attributable to shareholders of the listed company was 0.131 billion yuan, an increase of 19.15% year-on-year. The net income attributable to shareholders of the listed company after deducting non-recurring gains and losses was 0.123 billion yuan, an increase of 19.14% year-on-year.

The translation is provided by third-party software.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.

汉森制药(002412.SZ)发布前三季度业绩，净利润1.31亿元，同比增长19.15%

hunan hansen pharmaceutical (002412.SZ) released its performance for the first three quarters, with a net income of 0.131 billion yuan, a year-on-year increase of 19.15%.

Risk Disclaimer

Statement